Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Appl Neuropsychol Adult. 2019 Oct 29;28(6):685–696. doi: 10.1080/23279095.2019.1683562

Table 2.

Demographic Characteristics of HIV/CocDx− and HIV/CocDx+ Groups

Group
Demographic
Variable
HIV/CocDx−
(N=33) M (SD)
HIV/CocDx+
(N=80) M (SD)
Test Statistic Effect
size
Age 42.76 (7.93) 42.75 (6.50) t (111)=.01 d=.00
Education (years) 13.55 (2.21) 13.03 (1.88) t (111)=1.27 d=.25
Estimated Verbal IQ 105.36 (8.37) 104.61 (8.29) t (110)=.43 d=.09
% Male 85% 73% X2 (1,N=113)=1.624 Øc=.12
% Caucasian 18% 9% X2 (1,N=113)=2.041 Øc =.13
CD4 Count 450.36 (242.16) 454.95 (273.34) t (107)=−0.08 d=.02
% AIDS 72% 65% X2 (1,N=112)=.702 Øc=−0.08
Major Depression 33% 36% X2 (1,N=112)=.087 Øc=0.03
Cocaine
Positive Toxicology 34% 58% X2 (1,N=111)=.087 Øc=0.07
Duration of Abuse and/or Dependence - 206.31 (153.12) - -
Alcohol
Abuse or Dependence 67% 34% X2 (1,N=113)=10.307* Øc=0.30
Duration of Abuse and/or Dependence 128.00 (82.68) 208.89 (217.39) t (40)=−.89 d=.49
Stimulants
Abuse or Dependence 88% 78% X2 (1,N=112)=1.448 Øc=0.11
Positive Toxicologya 0% 0.01% X2 (1,N=111)=.409 Øc=.06
Duration of Abuse and/or Dependence 172.00 (144.07) 157.29 (140.57) t (16)=.18 d=.10
Opiates
Abuse or Dependence 88% 81% X2 (1,N=112)=.634 Øc=0.08
Positive Toxicology 0% 3% X2 (1,N=112)=.825 Øc=0.09
Duration of Abuse and/or Dependence 156.29 (40.60) 300.80 (373.72) t (11)=−.65 d=.54
Cannabis
Abuse or Dependence 78% 45% X2 (1,N=112)=10.113* Øc=0.08
Positive Toxicology 9% 19% X2 (1,N=112)=1.55 Øc=0.12
Duration of Abuse and/or Dependence 57.00 (72.12) 257.44 (199.07) t (18)=−1.39 d=1.34

Abbreviation key. M (SD)=Mean and standard deviation. HIV/CocDx−=HIV infected participants who did not meet diagnostic criteria for lifetime or current cocaine abuse or dependence. HIV/CocDx+=HIV who did not meet diagnostic criteria for lifetime or current cocaine abuse or dependence; IQ= Intelligence Quotient; CD4=Cluster of Differentiation 4; AIDS=Acquired Immunodeficiency Syndrome

*

p < .005

a

Amphetamines